 - Patients must have measurable and histologically or cytologically confirmed thyroid cancer with a BRAF V600E or V600K c. 1799 T to A and c.1799_1800TGAA mutation that is not considered curable by surgery; confirmation will be done at Memorial Sloan Kettering MSK; only tumors with a BRAFV600E or BRAFV600K mutation will be eligible for the clinical study; BRAF status will be assessed in a Clinical Laboratory Improvement Amendments CLIA certified laboratory; BRAF status may also be tested with any Food and Drug Administration FDA-approved test such as Cobas 4800 BRAF V600 Mutation Test 